WallStSmart

MEDIFAST INC (MED)vsService Corporation International (SCI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Service Corporation International generates 1279% more annual revenue ($4.37B vs $316.93M). SCI leads profitability with a 12.3% profit margin vs -8.1%. MED appears more attractively valued with a PEG of 0.97. SCI earns a higher WallStSmart Score of 60/100 (C+).

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.0Quality: 8.5
Piotroski: 2/9Altman Z: 5.09

SCI

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.5Value: 5.7Quality: 3.0
Piotroski: 4/9Altman Z: 0.48

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MED4 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.0910/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.978/10

Growing faster than its price suggests

SCI2 strengths · Avg: 9.0/10
Return on EquityProfitability
40.9%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
21.0%8/10

Strong operational efficiency at 21.0%

Areas to Watch

MED4 concerns · Avg: 2.5/10
Market CapQuality
$141.66M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-10.1%2/10

ROE of -10.1% — below average capital efficiency

Revenue GrowthGrowth
-27.6%2/10

Revenue declined 27.6%

SCI4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

EPS GrowthGrowth
4.7%4/10

4.7% earnings growth

Altman Z-ScoreHealth
0.482/10

Distress zone — elevated risk

Debt/EquityHealth
3.451/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : MED

The strongest argument for MED centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : SCI

The strongest argument for SCI centers on Return on Equity, Operating Margin. PEG of 1.48 suggests the stock is reasonably priced for its growth.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : SCI

The primary concerns for SCI are Revenue Growth, EPS Growth, Altman Z-Score. Debt-to-equity of 3.45 is elevated, increasing financial risk.

Key Dynamics to Monitor

MED profiles as a turnaround stock while SCI is a value play — different risk/reward profiles.

SCI carries more volatility with a beta of 0.81 — expect wider price swings.

SCI is growing revenue faster at 3.6% — sustainability is the question.

SCI generates stronger free cash flow (143M), providing more financial flexibility.

Bottom Line

SCI scores higher overall (60/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Service Corporation International

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Service Corporation International offers death care products and services in the United States and Canada. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?